BCBrent A. Craven

Brent A. Craven

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Brent A. Craven has a total of 114 co-authors. Here are the top co-authors by number of shared publications:

  • Kenneth I. Aycock

    Center for Devices and Radiological Health, Office of Science and Engineering Laboratories, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, UNITED STATES

    9 shared publications
  • Keefe B. Manning

    Department of Biomedical Engineering, The Pennsylvania State University, University Park, PA, 16802, USA; Department of Surgery, Penn State College of Medicine, Hershey, PA, 17033, USA

    6 shared publications
  • Francesco Costanzo

    Department of Engineering Science and Mechanics, The Pennsylvania State University , W315 Millennium Science Complex, 491 Pollock Road , University Park, PA 16802

    4 shared publications
  • Keefe B. Manning

    Department of Biomedical Engineering, Pennsylvania State University, University Park, USA

    4 shared publications
  • Scott D. Simon

    Department of Neurosurgery, Penn State College of Medicine , 700 HMC Crescent Road , Hershey, PA 17033

    4 shared publications
  • Jacob E. Sever

    Department of Biomedical Engineering, Pennsylvania State University, University Park, PA, United States

    3 shared publications

Latest Publications

  • An In Vitro Study of Embolus Migration in an Anatomical Cerebrovascular Model

    by Saurabh Bhardwaj, Daniel Khalil, Jose L. Monclova, Nicholas Etter, Francesco Costanzo, Scott D. Simon, Brent A. Craven, Keefe B. Manning

    Acute ischemic stroke (AIS) remains a driver of mortality and long-term impairment, with clinical outcomes depending strongly on the final lodging site of emboli within the cerebrovasculature. However, the physical mechanisms governing embolus migration and partitioning remain incompletely understood. Further, due to the paucity of experimental data in realistic anatomical models under pulsatile flow conditions, computational modeling of embolus migration in AIS remains largely unvalidated. The study objective is to acquire experimental benchmark data of embolus migration in an in vitro anatomical model comprising the aorta and the cerebrovasculature. Experiments are performed under pulsatile flow to quantify the migration of 480 rigid nylon spheres (1.58–4.76 mm) and 160 deformable blood emboli (2.53–3.95 mm). Emboli are injected into both Newtonian and non-Newtonian blood analogs to evaluate the influence of size, deformability, and fluid rheology. Results demonstrate an inverse relationship between embolus size and the propensity to migrate into the cerebrovasculature. Furthermore, when comparing emboli of similar dimensions, deformable blood clots exhibited consistently higher migration rates to the supra-aortic branches. While rheology slightly influences the migration of rigid spheres, it has a negligible effect on the partitioning of blood emboli. These findings suggest that embolus deformability plays a more dominant role than rheology in dictating whether realistic blood emboli migrate to the cerebral circulation. Consequently, to predict embolus trajectories and lodging sites in AIS, future in silico studies should incorporate fluid–structure interaction modeling to account for realistic clot deformability.

  • Open Access

    Computational modeling and simulation for medical devices: a summary of the 2024 FDA/MDIC Symposium

    by Brent A Craven, Christopher A Basciano, Payman Afshari, Kenneth I Aycock, Jeffrey J Ballyns, Andrew P Baumann, Jeffrey E Bischoff, Jeff Bodner, Paul Briant, Mark Driscoll, et al.

    Computational modeling and simulation (CM&S) is a powerful tool that can be used to support the development, evaluation, and regulatory authorization of medical devices. CM&S can provide valuable insights into device performance, safety, and effectiveness, as well as reduce the need for animal or human testing. Computational models are, however, idealized digital representations that often have many assumptions and need to be credible before they are used in decision making that could incur patient harm. While the medical device community has made great strides to advance the use of CM&S, a number of challenges remain. To begin addressing these challenges, the US Food and Drug Administration (FDA) and the Medical Device Innovation Consortium (MDIC) co-sponsored the FDA/MDIC Symposium on Computational Modeling and Simulation on April 16–17, 2024 in College Park, Maryland, USA, where attendees from around the world convened to hear from leaders in the field through a unique blend of invited presentations and interactive panel discussions. The symposium agenda covered several major themes, including credibility considerations for CM&S used across the medical device total product life cycle, practical examples of performing model credibility assessment, and the use of CM&S for clinical decision making and the emerging areas of in silico clinical trials and digital twins. The objective of this article is to summarize the major takeaways of the symposium. We first provide an overview of the invited presentations followed by summaries of the topics covered during the interactive panel discussions. In doing so, we highlight the main takeaways and identify areas in which panelists had shared perspectives or differences of opinion. Next, we present the results of a survey conducted at the symposium that sought attendees’ perspectives on different aspects of medical device CM&S. Finally, we conclude by summarizing the major outcomes of the symposium, including areas where more work and investment are needed to advance the field.


  • Single‐Pass System to Characterize the Effects of Blood Species and Hematocrit on Flow‐Induced Hemolysis

    by Sailahari V. Ponnaluri, Moustafa Meki, Luke H. Herbertson, Qijin Lu, Brent A. Craven, Richard A. Malinauskas

    Background: To assess hemolysis potential, blood pump developers frequently perform in vitro testing in accordance with the ASTM F1841 standard. However, options in test parameters such as blood species, anticoagulant, and blood collection and preparation methods can lead to inconsistent hemolysis results. Methods: To improve in vitro hemolysis test sensitivity and characterize the impact of species and hematocrit (HCT) on flow‐induced hemolysis, a pressure‐driven, single‐pass micro‐nozzle test system with short blood exposure times was developed. To compare different blood species, porcine, bovine, ovine, and human blood pools were adjusted to 35% HCT, and 2.7 mL blood aliquots were pneumatically injected at different flow rates through two converging nozzle tips with diameters of 250 and 410 μm. Plasma‐free hemoglobin (pfHb) concentration was measured to assess hemolysis after passing through the nozzle tip model. Additionally, porcine blood was tested at 25%, 35%, and 45% HCT using the 410 μm nozzle. Results: Using a single blood source, the repeatability for a single nozzle and reproducibility based on five separate nozzles were characterized. Results for the nozzles were consistent, with coefficients of variation of 0.5% for flow rate and less than 16% for pfHb levels. Hemolysis increased markedly with flow rate for all species, with pfHb levels being lowest for ovine and bovine blood and highest for human blood. Additionally, hemolysis increased non‐linearly with increasing HCT. Conclusion: The nozzle tip model can be used to examine other blood factors that impact hemolysis and to support and advance computational fluid dynamics hemolysis simulations.


  • Open Access

    Genetic and Anatomical Determinants of Olfaction in Dogs and Wild Canids

    by Alice Mouton, Deborah J Bird, Gang Li, Brent A Craven, Jonathan M Levine, Marco Morselli, Matteo Pellegrini, Blaire Van Valkenburgh, Robert K Wayne, William J Murphy

    Understanding the anatomical and genetic basis of complex phenotypic traits has long been a challenge for biological research. Domestic dogs offer a compelling model as they demonstrate more phenotypic variation than any other vertebrate species. Dogs have been intensely selected for specific traits and abilities, directly or indirectly, over the past 15,000 years since their initial domestication from the gray wolf. Because olfaction plays a central role in critical tasks, such as the detection of drugs, diseases, and explosives, as well as human rescue, we compared relative olfactory capacity across dog breeds and assessed changes to the canine olfactory system to their direct ancestors, wolves, and coyotes. We conducted a cross-disciplinary survey of olfactory anatomy, olfactory receptor (OR) gene variation, and OR gene expression in domestic dogs. Through comparisons to their closest wild canid relatives, the gray wolf and coyote, we show that domestic dogs might have lost functional OR genes commensurate with a documented reduction in nasal morphology as an outcome of the domestication process prior to breed formation. Critically, within domestic dogs alone, we found no genetic or morphological profile shared among functional or genealogical breed groupings, such as scent hounds, that might indicate evidence of any human-directed selection for enhanced olfaction. Instead, our results suggest that superior scent detection dogs likely owe their success to advantageous behavioral traits and training rather than an “olfactory edge” provided by morphology or genes.


  • Open Access

    Corrigendum: Modeling flow in an in vitro anatomical cerebrovascular model with experimental validation

    by Saurabh Bhardwaj, Brent A. Craven, Jacob E. Sever, Francesco Costanzo, Scott D. Simon, Keefe B. Manning

    In the published article, there was an error in Figure 3b as published. The simulation was based on an incorrect scale and the values have been updated. The corrected Figure 3b and its caption appear below. In the published article, there was an error in Figure 5 as published. The simulation was conducted using an incorrect scale and these values have been revised. The corrected Figure 5 and its caption appear below. In the published article, there was an error in Table 2 as published. The simulation was conducted using an incorrect scale and these values have been revised. The corrected Table 2 and its caption appear below.In In the published article, there was an error in Table 3 as published. The simulation was conducted using an incorrect scale and these values have been revised. The corrected

  • Open Access

    Toward trustworthy medical device in silico clinical trials: a hierarchical framework for establishing credibility and strategies for overcoming key challenges

    by Kenneth I. Aycock, Tom Battisti, Ashley Peterson, Jiang Yao, Steven Kreuzer, Claudio Capelli, Sanjay Pant, Pras Pathmanathan, David M. Hoganson, Steve M. Levine, et al.

    Computational models of patients and medical devices can be combined to perform an in silico clinical trial (ISCT) to investigate questions related to device safety and/or effectiveness across the total product life cycle. ISCTs can potentially accelerate product development by more quickly informing device design and testing or they could be used to refine, reduce, or in some cases to completely replace human subjects in a clinical trial. There are numerous potential benefits of ISCTs. An important caveat, however, is that an ISCT is a virtual representation of the real world that has to be shown to be credible before being relied upon to make decisions that have the potential to cause patient harm. There are many challenges to establishing ISCT credibility. ISCTs can integrate many different submodels that potentially use different modeling types (e.g., physics-based, data-driven, rule-based) that necessitate different strategies and approaches for generating credibility evidence. ISCT submodels can include those for the medical device, the patient, the interaction of the device and patient, generating virtual patients, clinical decision making and simulating an intervention (e.g., device implantation), and translating acute physics-based simulation outputs to health-related clinical outcomes (e.g., device safety and/or effectiveness endpoints). Establishing the credibility of each ISCT submodel is challenging, but is nonetheless important because inaccurate output from a single submodel could potentially compromise the credibility of the entire ISCT. The objective of this study is to begin addressing some of these challenges and to identify general strategies for establishing ISCT credibility. Most notably, we propose a hierarchical approach for assessing the credibility of an ISCT that involves systematically gathering credibility evidence for each ISCT submodel in isolation before demonstrating credibility of the full ISCT. Also, following FDA Guidance for assessing computational model credibility, we provide suggestions for ways to clearly describe each of the ISCT submodels and the full ISCT, discuss considerations for performing an ISCT model risk assessment, identify common challenges to demonstrating ISCT credibility, and present strategies for addressing these challenges using our proposed hierarchical approach. Finally, in the Appendix we illustrate the many concepts described here using a hypothetical ISCT example.


  • Open Access

    Genetic and anatomical determinants of olfaction in dogs and wild canids

    by Alice Mouton, Deborah Bird, Gang Li, Brent A. Craven, Jonathan M. Levine, Marco Morselli, Matteo Pellegrini, Blaire Van Valkenburgh, Robert K. Wayne, William J. Murphy

    Understanding the anatomical and genetic basis of complex phenotypic traits has long been a challenge for biological research. Domestic dogs offer a compelling model as they demonstrate more phenotypic variation than any other vertebrate species. Dogs have been intensely selected for specific traits and abilities, directly or indirectly, over the past 15,000 years since their initial domestication from the gray wolf. Because olfaction plays a central role in critical tasks, such as the detection of drugs, diseases, and explosives, as well as human rescue, we compared relative olfactory capacity across dog breeds and assessed changes to the canine olfactory system resulting from domestication. We conducted a cross-disciplinary survey of olfactory anatomy, olfactory receptor (OR) gene variation, and OR gene expression in domestic dogs. Through comparisons to their closest wild canid relatives, the gray wolf and coyote, we show that domestic dogs might have lost functional OR genes commensurate with a documented reduction in nasal morphology during domestication. Critically, within domestic dogs alone, we found no genetic or morphological profile shared among functional or genealogical breed groupings, such as scent hounds, that might indicate evidence of any human-directed selection for enhanced olfaction. Instead, our results suggest that superior scent detection dogs likely owe their success to advantageous behavioral traits and training rather than an “olfactory edge” provided by morphology or genes.


  • Practical implications of the erroneous treatment of exposure time in the Eulerian hemolysis power law model

    by Mohammad M. Faghih, Brent A. Craven, M. Keith Sharp

    Background: Eulerian and Lagrangian power‐law formulations are both widely used for computational fluid dynamics (CFD) to predict flow‐induced hemolysis in blood‐contacting medical devices. Both are based on the same empirical power‐law correlation between hemolysis and the shear stress and exposure time. In the Lagrangian approach, blood damage is predicted by tracking both the stress and exposure time along a finite number of pathlines in the domain. In the Eulerian approach, a scalar transport equation is solved for a time‐linearized damage index within the entire domain. Previous analytical work has demonstrated that there is a fundamental problem with the treatment of exposure time in the Eulerian model formulation such that the only condition under which the model correctly represents the true exposure time is in a flow field with no streamwise velocity variation. However, the practical implications of this limitation have yet to be thoroughly investigated.Methods: In this study, we demonstrate the inaccuracy of Eulerian hemolysis power‐law model predictions due to the erroneous treatment of exposure time by systematically considering four benchmark test cases with increasing degrees of flow acceleration: Poiseuille flow through a straight tube, inclined Couette flow, and flow through a converging tube with two different convergence ratios.Results: Compared with Lagrangian predictions, we show that, as flow acceleration becomes more pronounced, the resultant inaccuracy in the Eulerian predictions increases. For the inclined Couette flow case, there is a small degree of flow acceleration that yields a discrepancy in the range of 10% between Lagrangian and Eulerian predictions. For flows with a larger degree of acceleration, as occurs in the converging tube flow cases, the discrepancy is considerably larger (up to 257%).Conclusion: The inaccuracy of hemolysis predictions due to the erroneous treatment of exposure time in the Eulerian power‐law model can be significant when there is streamwise velocity variation in the flow field. These results may partially explain the extremely large variability in CFD hemolysis predictions reported in the literature between Lagrangian and Eulerian models.


  • Open Access

    Modeling flow in an in vitro anatomical cerebrovascular model with experimental validation

    by Saurabh Bhardwaj, Brent A. Craven, Jacob E. Sever, Francesco Costanzo, Scott D. Simon, Keefe B. Manning

    Acute ischemic stroke (AIS) is a leading cause of mortality that occurs when an embolus becomes lodged in the cerebral vasculature and obstructs blood flow in the brain. The severity of AIS is determined by the location and how extensively emboli become lodged, which are dictated in large part by the cerebral flow and the dynamics of embolus migration which are difficult to measure in vivo in AIS patients. Computational fluid dynamics (CFD) can be used to predict the patient-specific hemodynamics and embolus migration and lodging in the cerebral vasculature to better understand the underlying mechanics of AIS. To be relied upon, however, the computational simulations must be verified and validated. In this study, a realistic in vitro experimental model and a corresponding computational model of the cerebral vasculature are established that can be used to investigate flow and embolus migration and lodging in the brain. First, the in vitro anatomical model is described, including how the flow distribution in the model is tuned to match physiological measurements from the literature. Measurements of pressure and flow rate for both normal and stroke conditions were acquired and corresponding CFD simulations were performed and compared with the experiments to validate the flow predictions. Overall, the CFD simulations were in relatively close agreement with the experiments, to within ±7% of the mean experimental data with many of the CFD predictions within the uncertainty of the experimental measurement. This work provides an in vitro benchmark data set for flow in a realistic cerebrovascular model and is a first step towards validating a computational model of AIS.


  • Open Access

    A sharp interface Lagrangian-Eulerian method for flexible-body fluid-structure interaction

    by Ebrahim M. Kolahdouz, David R. Wells, Simone Rossi, Kenneth I. Aycock, Brent A. Craven, Boyce E. Griffith

    This paper introduces a sharp-interface approach to simulating fluid-structure interaction involving flexible bodies described by general nonlinear material models and across a broad range of mass density ratios. This new flexible-body immersed Lagrangian-Eulerian (ILE) approach incorporates the geometrical and domain solution flexibility of the immersed boundary (IB) method with an accuracy comparable to body-fitted approaches that sharply resolve flows and stresses up to the fluid-structure interface. Unlike many IB methods, our ILE formulation uses distinct momentum equations for the fluid and solid subregions with a Dirichlet-Neumann coupling strategy that connects fluid and solid subproblems through simple interface conditions. We use a penalty method involving two representations of the fluid-structure interface. These two representations are connected by approximate Lagrange multiplier forces that impose kinematic interface conditions. This approach also enables the use of multi-rate time stepping, which allows us to take different time step sizes for the fluid and structure subproblems. Our fluid solver relies on an immersed interface method for discrete surfaces to impose stress jump conditions along complex interfaces. The dynamics of the volumetric structural mesh are determined using a standard finite element approach to large-deformation nonlinear elasticity via a nearly incompressible solid mechanics formulation. This formulation also readily accommodates compressible structures for cases in which part of the solid boundary does not contact the incompressible fluid. Comparisons are made with computational and experimental benchmarks. We also demonstrate the capabilities of this methodology by applying it to model the transport and capture of a cylindrical blood clot in an inferior vena cava filter.